Bionano Genomics (BNGO) Common Equity (2017 - 2026)

Bionano Genomics' Common Equity history runs 10 years deep, the most recent figure standing at $37.5 million for Q1 2026.

• In Q1 2026, Common Equity fell 22.26% year-over-year to $37.5 million; the TTM figure through Mar 2026 stood at $37.5 million (down 22.26% YoY), while the FY2025 annual figure was $44.4 million, up 25.58% from the prior year.
• Common Equity came in at $37.5 million for Q1 2026 at Bionano Genomics, down from $44.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $311.2 million in Q1 2022 to a low of $35.4 million in Q4 2024.
• A 5-year average of $133.0 million and a median of $82.8 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 64.24% in 2024 and climbed 25.58% in 2025, its largest moves.
• Bionano Genomics' Common Equity stood at $249.4 million in 2022, then plunged by 61.44% to $96.2 million in 2023, then sank by 63.21% to $35.4 million in 2024, then gained by 25.58% to $44.4 million in 2025, then dropped by 15.67% to $37.5 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $37.5 million, $44.4 million, and $49.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison